Mylan (MYL) Gets Unfavorable Ruling in Generic Xopenex Trial, Will Challenge
Up)
Mylan Inc. (Nasdaq: MYL) announced that a jury has rendered an unfavorable verdict in a patent infringement lawsuit filed by Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., against Mylan Inc., Mylan Pharmaceuticals Inc., Dey Inc. and Dey Pharma, L.P. in relation to Dey's Abbreviated New Drug Application (ANDA) for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL product.
The trial was held in the United States District Court for the District of Delaware. Levalbuterol HCl is the generic version of Sunovion's Xopenex.
The verdict includes an award of $18 million.
Mylan CEO Heather Bresch commented, "While this is not a significant product for Mylan, we firmly believe that the jury has erred and intend to seek reversal through post-trial motions and, if necessary, an appeal of the verdict and the damages award."
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The trial was held in the United States District Court for the District of Delaware. Levalbuterol HCl is the generic version of Sunovion's Xopenex.
The verdict includes an award of $18 million.
Mylan CEO Heather Bresch commented, "While this is not a significant product for Mylan, we firmly believe that the jury has erred and intend to seek reversal through post-trial motions and, if necessary, an appeal of the verdict and the damages award."
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
- Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
